Cargando…

Topical rapamycin for facial angiofibromas in tuberous sclerosis complex

Facial angiofibromas are a common cutaneous manifestation of tuberous sclerosis complex. Although angiofibromas are usually asymptomatic, they can be highly disfiguring and can have a significant impact on patient quality of life. Treatment for facial angiofibromas is challenging. Recently, topical...

Descripción completa

Detalles Bibliográficos
Autor principal: Safa, Gilles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5496009/
https://www.ncbi.nlm.nih.gov/pubmed/28690858
http://dx.doi.org/10.1093/omcr/omx029
_version_ 1783247884218531840
author Safa, Gilles
author_facet Safa, Gilles
author_sort Safa, Gilles
collection PubMed
description Facial angiofibromas are a common cutaneous manifestation of tuberous sclerosis complex. Although angiofibromas are usually asymptomatic, they can be highly disfiguring and can have a significant impact on patient quality of life. Treatment for facial angiofibromas is challenging. Recently, topical rapamycin has been proposed as an effective option to treat angiofibromas. Herein is reported a case of a 27-year-old woman whose facial angiofibromas were successfully treated with topical rapamycin without relevant side effects.
format Online
Article
Text
id pubmed-5496009
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-54960092017-07-07 Topical rapamycin for facial angiofibromas in tuberous sclerosis complex Safa, Gilles Oxf Med Case Reports Case Report Facial angiofibromas are a common cutaneous manifestation of tuberous sclerosis complex. Although angiofibromas are usually asymptomatic, they can be highly disfiguring and can have a significant impact on patient quality of life. Treatment for facial angiofibromas is challenging. Recently, topical rapamycin has been proposed as an effective option to treat angiofibromas. Herein is reported a case of a 27-year-old woman whose facial angiofibromas were successfully treated with topical rapamycin without relevant side effects. Oxford University Press 2017-07-04 /pmc/articles/PMC5496009/ /pubmed/28690858 http://dx.doi.org/10.1093/omcr/omx029 Text en © The Author 2017. Published by Oxford University Press. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Case Report
Safa, Gilles
Topical rapamycin for facial angiofibromas in tuberous sclerosis complex
title Topical rapamycin for facial angiofibromas in tuberous sclerosis complex
title_full Topical rapamycin for facial angiofibromas in tuberous sclerosis complex
title_fullStr Topical rapamycin for facial angiofibromas in tuberous sclerosis complex
title_full_unstemmed Topical rapamycin for facial angiofibromas in tuberous sclerosis complex
title_short Topical rapamycin for facial angiofibromas in tuberous sclerosis complex
title_sort topical rapamycin for facial angiofibromas in tuberous sclerosis complex
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5496009/
https://www.ncbi.nlm.nih.gov/pubmed/28690858
http://dx.doi.org/10.1093/omcr/omx029
work_keys_str_mv AT safagilles topicalrapamycinforfacialangiofibromasintuberoussclerosiscomplex